Compare Frontline Plc Ordinary Shares (FRO) vs Merck & Co., Inc. (MRK) Price & Performance

Frontline Plc Ordinary SharesTrade

Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Frontline Plc Ordinary Shares vs Merck & Co., Inc. — how do they compare? Frontline Plc Ordinary Shares trades at $56.55 (market cap $12.52B), while Merck & Co., Inc. trades at $144.64 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 28.1× Frontline Plc Ordinary Shares's market cap, and Frontline Plc Ordinary Shares pays the higher dividend (9.56%). Which is the better fit depends on your goals — on Pluang, investors hold Frontline Plc Ordinary Shares for 0 Days and Merck & Co., Inc. for 98 Days on average.

	FRO	MRK
Market Cap	$12.52B	$351.28B
Volume	6,375,509	7,969,665
Sector	Industrials	Health
52-Week High	$56.26	$156.43
52-Week Low	$20.58	$82.49
Typical Hold Time	0 Days	98 Days
Enterprise Value	$14.64B	$398.04B
Dividend Yield	9.56%	2.39%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Frontline Plc Ordinary Shares

No Aura AI signal available yet.

Merck & Co., Inc.

Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.

The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FRO

77% Buy23% Sell

Avg holding period · 0 Days

MRK

18% Buy82% Sell

Avg holding period · 98 Days

Top news

Latest headlines on both assets

FRO

View details →

MRK

Cantor Fitzgerald raises price targets on Eli Lilly, AbbVie, Merck, and Pfizer amid mixed growth outlooks.24/7 Wall Street · 6 hours agoBullish Global DPP-4 inhibitors market to grow to $15.5B by 2032, driven by type 2 diabetes demand and generics expansion.PRNewsWire · 1 day agoNeutral HP, Merck, and Seagate paid dividends on Oct 7, with Merck leading in per-share payout and HP offering the highest yield.24/7 Wall Street · 1 day agoBullish View details →

About Frontline Plc Ordinary Shares

Frontline operates a fleet of oil tankers that transport crude oil by sea. Its vessels serve global energy trading routes.

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.